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The SULSA Assay Development Fund:
accelerating translation of new biology
from academia to pharma
Stuart P. McElroy1, s.mcelroy@dundee.ac.uk, Philip S. Jones1 and Denise V. Barrault2
With industry increasingly sourcing preclinical drug discovery projects from academia it is important
that new academic discoveries are enabled through translation with HTS-ready assays. However, many
scientifically interesting, novel molecular targets lack associated high-quality, robust assays suitable for
hit finding and development. To bridge this gap, the Scottish Universities Life Sciences Alliance (SULSA)
established a fund to develop assays to meet quality criteria such as those of the European Lead Factory. A
diverse project portfolio was quickly assembled, and a review of the learnings and successful outcomes
showed this fund as a new highly cost-effective model for leveraging significant follow-on resources,
training early-career scientists and establishing a culture of translational drug discovery in the academic
community.
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Seismic changes are underway in the methods
and organisational models used to discover
modern medicines in response to the decline in
productivity from traditional pharmaceutical
industry approaches. Notable among these
changes is the shift towards open innovation,
which has promoted synergistic, collaborative
programmes between different sectors includ-
ing academia, biotech, charities, public institutes,
CROs and major pharma companies. Major
initiatives have been established to promote
these collaborative approaches. For example, the
EU commission and European Federation of
Pharmaceutical Industries and Associations
(EFPIA) have funded, through the s2 billion In-
novative Medicines Initiative (IMI), the creation of
the European Lead Factory (ELF), a collaborative1359-6446/ 2016 The Author(s). Published by Elsevier Ltd. This is an 
http://dx.doi.org/10.1016/j.drudis.2016.09.028 public–private partnership delivering innovative
drug discovery starting points backed with an
investment of s196 million (http://www.
europeanleadfactory.eu/) [1,2].
A key initial step for translational biology to
succeed in delivering nascent medicines is the
identification of high-quality chemical matter
that predictably modulates a desired biological
effect [3]. Multiple methods exist for generating
or discovering lead compounds but all rely on
access to one or more assays that are repro-
ducible and have a capacity or throughput
matched to the techniques being employed. The
expertise and facilities required to create these
high-throughput assays have traditionally re-
sided in pharma companies and lack of access
has limited the approaches employed by groups
outside of industry. This is particularly evident foropen access article under the CC BY-NC-ND license (http://creativecommlife science academics who rarely have the ex-
pertise or equipment to carry out HTS on the
scale of 0.5 million compounds as conducted
in large pharma or the ELF.
The pharmaceutical industry has thus been
increasing its efforts to collaborate with uni-
versities and benefit from translational research
in a bid to enhance innovation in early-stage
drug discovery, essentially to bolster their
shrinking drug pipelines and counteract the
ongoing patent cliff. Over the past 10–15 years
this has resulted in significant inward investment
from pharma towards universities and a signifi-
cant rise in the number of academic drug dis-
covery groups [4–6]. University scientists have, to
their advantage, witnessed a rise in industry-
sponsored schemes aimed at screening novel
targets and biological assays, and exploiting newons.org/licenses/by-nc-nd/4.0/).
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BOX 1
European Lead Factory technical
acceptance criteria
 Minimally 384 wells (max 30 ml)
 Homogenous assay (no washing steps)
 Defined endpoint
 Z-prime >0.6
 Readout stability >1 h
 S/B signal >3
 Incubation times <4 h
 DMSO tolerance: minimum 0.5%
 All reagents minimally 8 h stable
 Recombinant proteins(s) >80% pure
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maintain these new initiatives, putative drug
targets emerging from basic science first need to
be enabled with HTS-ready assays and, as
mentioned, developing such assays requires
knowledge and experience, which many aca-
demic researchers will probably not have been
exposed to. In particular, there is a need to
understand acceptable experimental robustness
criteria and comprehend the pitfalls and po-
tential liabilities involved in screening [3,8]. This
knowledge gap in the academic community was
identified by the Scottish Universities Life
Sciences Alliance (SULSA), which responded by
establishing a pump-priming fund called the
SULSA Assay Development Fund (SULSA-ADF)
administered by the European Screening Centre
(ESC) in Newhouse, Lanarkshire (http://www.
lifesci.dundee.ac.uk/research/esc).
The aim of the SULSA-ADF was to source novel
targets from the SULSA community and develop
HTS-ready assays to a standard acceptable for
submission to the ELF. The ELF is a European-
wide initiative providing academics and small-
medium enterprises (SMEs) access to large-scale
HTS of proprietary industry-grade libraries [9,10].0 1 
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FIGURE 1
The SULSA Assay Development Fund workflow. Desig
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the target must come with an assay that meets a
number of stringent quality control and logistical
criteria (Box 1). Looking at these criteria, it is not
hard to see that many academic labs struggle to
meet them. For example, the very first specifi-
cation: ‘minimally 384-well’, is a format not often
used in university labs because HTS is not a
primary consideration when acquiring equip-
ment. Although the fund aimed to develop
assays meeting the ELF criteria, assays devel-
oped to this level of robustness could also be
eligible for a number of other industry-funded
programmes such as Astra Zeneca’s Open In-
novation Portal, or GSK’s Discovery Partnerships
with Academia (DPAc). Submitting to these kinds
of schemes was encouraged in the community
to maximise the positive outcomes of the SULSA-
ADF.
Scope, structure and aims of the SULSA-
ADF
SULSA is a research pool that was established in
2008 with funds of £27 million from the Scottish
Funding Council (SFC). It is a strategic collabo-
ration between six member Scottish universities:
Aberdeen, Dundee, Edinburgh, Glasgow, St.
Andrews and Strathclyde. The aim of the pool is
to enhance research excellence in the life
sciences in Scotland, by joining up research
strategy for larger projects and co-investing and
sharing core research facilities. SULSA also has a
remit to enhance translational research, which
sparked the idea for a translational fund, and led
to the creation of the SULSA-ADF in 2014, en-
abled with a modest investment of £300 000.
A competitive call for proposals was devel-
oped and widely advertised throughout Scot-
land to attract the best and most innovative
academic projects with the aim of recruiting
18 projects to deliver 12 assays successfully2 3 4 5 6 7
ibility study
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ned to ensure efficient use of resources and maximisdeveloped to ELF standards. Project submissions
are reviewed by a panel of four experts who use
their extensive industrial and academic drug
discovery experience to score the proposals.
Proposals are accepted when there is a clear
unmet medical need or they have the potential
for delivering a novel therapy. They must also
have a clear rationale for developing an HTS-
compatible assay using established screening
technologies (i.e. no blue-sky development of
unprecedented assay concepts). Evidence for
the availability of active reagents is also
requested. Upon project acceptance, an initial
teleconference between ESC scientists and the
project owner (PO) is arranged to plan the assay
development strategy, identify material
requirements and set appropriate timelines.
The fund provides two expert ESC assay de-
velopment scientists to industrialise the assay, as
well as all commercially available consumables.
Applicants are expected to provide any non-
commercially available reagents such as re-
combinant proteins, bespoke substrates or
proprietary cell lines. However, if required, they
can directly access up to £3000 to help with
protein production. The intention is to use the
SULSA funding as efficiently as possible by de-
veloping assays rapidly, avoiding potentially
open-ended development and trouble-shooting
that can tie up resources and extend portfolio
development timelines. A streamlined workflow
(Fig. 1) has been designed so that, upon receipt
of reagents, a 2-week feasibility assessment is
undertaken for each assay. If a promising assay
window cannot be established during this pe-
riod then the assay is returned to the PO with
recommendations on how to improve on the
assay starting point. They are invited to resubmit
the project with supporting data once they have
successfully implemented the suggested
improvements. For projects judged to have a 8
eline in weeks
Drug Discovery Today 
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TABLE 1
Project delivery goals and achievements of the SULSA-ADF
Original goal Achieved
Project recruitment 18 22
Assays developed to European Lead Factory (ELF) criteria 12 13
Projects submitted to ELF 10 7 (2 in preparation)
Projects accepted by ELF 6 5 (1 under review)
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FIGURE 2
The time taken to development each assay meets the 8 week target for the majority of the projects,
highlighting it as an efficient streamlined process for translation.
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with the aim of meeting the ELF assay technical
criteria. The whole process from start to finish is
intended to take no longer than 8 weeks per
project on average. Although the primary de-
liverable for SULSA-ADF is a standard operating
procedure (SOP) and associated data, a sec-
ondary aim is to run a small-scale pilot screen
against 7000 compounds. These compounds
consist of the NIH Clinical Collections set, the
Selleckchem FDA-Approved Drug Library (http://
www.selleckchem.com/) and a selection of
structurally diverse lead-like molecules selected
from the BioAscent compound cloud (http://
www.bioascent.com/compoundcloud/). Run-
ning this pilot screen provides useful data on the
robustness of the assay over a normal screening
day and provides an assessment of assay and
target promiscuity in the form of the primary hit
and confirmation rates. These data can then be
used to inform the design of a screening cascade
if the target is screened elsewhere, such as in the
ELF. It is also a potential source of new hit
compounds that the PO can exploit as chemical
tools, reference molecules or starting points for
drug development campaigns.
Knowledge exchange and student training
The SULSA-ADF creates an excellent opportunity
for knowledge exchange and training for PhD
students and postdoctoral researchers. This is
presented as an offer to scientists from the POs’
labs to work at the ESC Newhouse on their assay
development project. We believe this maximises
the chances of project success by acknowledg-
ing that the best person to develop a targeted
assay is the person who has an in-depth practical
experience of the biology underlying it. It also
provides early career researchers with a good
knowledge of this key aspect of drug discovery,
in what amounts to an intensive residential
training course. They can then take this new
knowledge back to their home institutions and
help incubate a culture of translational drug
discovery, creating the potential for a virtuous
cycle of new project submissions to the fund. In
addition, young researchers will be better
equipped either to exploit their own basic sci-
entific discoveries if they remain in academia orwill have extra skills to strengthen their CV if
seeking employment in industry.
The availability of a scientist from a PO’s lab to
help with the assay development is established
during the first project meeting, and plans are
made for accommodating their stay at the ESC
Newhouse. Unfortunately the fund does not
cover living and travelling expenses, an obvious
weakness of the current format. However,
funding for this aspect of the project has always
been met by the POs, who see the significant
value of this training opportunity for students
and staff. For example, in one Glasgow University
project a knowledge exchange funding stream
covered all of the costs associated with the
placement.
Portfolio building, outcomes and impact
An immediate logistical requirement was to
rapidly recruit a large enough number of project
submissions to build a suitable portfolio. The
scheme was devised as an open call to the
community, in the hope of promoting a con-
tinual influx of molecular-target-based projects.
However, project submissions were usually only
forthcoming following an intense period of
community engagement. Raising awareness
among the six SULSA universities involved ad-
vertising on the SULSA website, direct emailcommunication to the Technology Transfer
Offices and researchers and, crucially, oral pre-
sentations and face-to-face networking. Net-
working proved to be the most productive
approach, because direct discussions with aca-
demics helped establish the suitability of their
project for the scheme and allowed an initial
discussion on potential assay formats. More than
70% of project submissions were sourced
through this approach.
Over the course of two years the project
recruitment and assay development goals of the
fund have been achieved (Table 1). Currently, 16
of 22 projects have been finished with 13 de-
veloped to ELF standards (Box 1). Of those failing
to meet the ELF standards one cell-based project
was completed but could not consistently obtain
Z0 values above 0.6 (a strict criteria within ELF),
and two projects were halted at the feasibility
stage because no suitable assay window was
established. Six projects are still active. Of the 14
completed assays the median time from the
initial planning meeting to completion of the
assay development report was 8 weeks (Fig. 2).
Most assays were completed in less than 12
weeks with three showing much longer time-
lines. These three assays encountered different
delaying issues comprising: limited resourcing
at the beginning of the SULSA-ADF; proteinwww.drugdiscoverytoday.com 201
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FIGURE 3
SULSA Assay Development Fund project portfolio overview detailing a % breakdown by (a) disease indication, (b) target class and (c) technology used to develop
the assays. Abbreviations: CNS, central nervous system disease; CV, cardiovascular disease; NTD, neglected tropical disease.
Featu
res
P
E
R
S
P
E
C
T
IV
Eproduction difficulties; and a cell line that re-
quired re-optimisation by the PO.
For the 13 projects meeting the ELF assay
criteria, seven have been submitted to the ELF
and all passed the technical check allowing them
to be sent for scientific review. At the time of
writing, five of these had been accepted into ELF
with one awaiting review. Of the projects that
met the ELF criteria, but were not submitted to
ELF, one was not pursued further by the PO, one
secured funding to run an HTS elsewhere and
there are a further two submissions for ELF in
preparation. With a mean cost per project at
£13 600 and the cost of a large HTS and follow-
up work within the ELF conservatively estimated
at £500 000, successful submissions to the ELF
clearly provide a significant return on invest-
ment. To date this is estimated to equate to an
excess of £2.5 million and is likely to increaseBOX 2
Quotes from Scottish Universities Life S
Fund (SULSA-ADF) applicants and stud
‘We only got so far in optimising our assay beca
equipment or the personnel with the skill set re
come and work at Newhouse where you are t
quickly where assay improvements should be 
how to set about applying these changes (as w
of equipment) was invaluable.’
‘The best aspect of the placement was the op
assays suitable for high throughput analysis an
satisfying to watch the basic molecular biolog
drug discovery process which may have real wo
therapeutic agent.’
‘Many of the jobs I have recently applied for in
With hands on experience in this process, my C
at Newhouse.’
202 www.drugdiscoverytoday.comconsiderably as the portfolio is completed this
year and the downstream benefits to the SULSA
University POs are fully realised.
As planned, we created a diverse portfolio as
can be seen when it is broken down by disease
area, target class and screening technology
adopted (Fig. 3). Of particular note, nearly one-
third of the portfolio is focused on infectious
diseases. Oncology represents the largest dis-
ease area and this probably reflects the research
interests of the academic community. Examining
the portfolio by target class there is a balance
between more-difficult targets, such as protein–
protein interactions (PPIs; 25%), protein–RNA
interactions (PRIs; 15%) and cAMP-binding pro-
teins (5%), and some traditionally more-drug-
gable classes, such as enzymes (35%), nuclear
receptors (15%) and cytokine receptors (5%). The
large number of PPIs and PRIs has also skewedciences Alliance Assay Development
ents.
use in my opinion we do not have either the
quired to do this efficiently. So being able to
hen surrounded by people who can identify
made and then pass on the knowledge of
ell as gaining experience with various pieces
portunity to translate molecular events to
d ultimately drug discovery. It is particularly
y I studied during my PhD progress into the
rld application and is the first step towards a
clude the development of molecular assays.
V is certainly strengthened thanks to my timethe assay technology towards fluorescence
polarisation assays, predominantly because of
the ease and cost efficiency of obtaining fluo-
rescently labelled peptides and RNA. Notable by
their absence are G-protein-coupled receptors
(GPCRs) and ion channels, which could reflect
reduced academic interest in this area or pos-
sibly indicate that assay development and
screening for these targets is so mature that
support from screening facilities is less in de-
mand.
In total, six of the 16 completed projects in the
portfolio were worked on by students and staff
from the PO’s lab-comprising three PhD stu-
dents, one Master’s student and two postdocs.
The scheme attracted a very high calibre of
individual. All of the students were in their final
year and close to writing up their theses, en-
suring they had a very high level of knowledge
around their research projects, they were very
technically adept in the lab and were highly
motivated to complete the work in a timely
manner. Mentoring of visiting-scientists was
principally undertaken by the two ESC assay
development scientists; although there was a
time-penalty associated with training, this was
typically no more than 2 weeks, at which point all
involved were near self-sufficiency in the lab.
Assessment of the benefit to these individuals
from the scheme is somewhat qualitative but
can be summed up in their own words (Box 2).
Concluding remarks
The SULSA-ADF allows scientists from Scottish
universities to unlock the translational potential
of new biology, by providing avenues for sig-
nificant follow-on funding leading to starting
Drug Discovery Today  Volume 22, Number 2  February 2017 PERSPECTIVE
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for impacts on human health. Rather than di-
rectly providing grant-style funding to university
academics, it has provided funds for ESC experts
to enable the basic biology with specific assay
development expertise tailored to an industry-
perspective, and leveraged existing industry-
grade facilities. The fund is meeting its prede-
fined goals and has already demonstrated sig-
nificant return on investment, shown by
significant leveraged funding and the impact it is
having on young researchers. It is fully expected
that it will continue to deliver at the same level as
it draws to completion. It has also resulted in
academic opportunities for POs with at least
three scientific publications detailing assay de-
velopment and screening outcomes currently in
preparation. Through this experience we believe
it is crucial to provide academics with access to
the necessary expertise and facilities that ensure
their research can be useful and attractive to the
pharma industry. By promoting this kind of
catalytic activity, we are supporting collaborative
efforts that engage all members of the scientific
community, ensuring that all sectors contribute
most efficiently towards improving human
health.
Training young university scientists by
transferring relevant translational knowledge
into the academic community ensures that, over
time, the gap between pharma and university
life sciences research diminishes, and a more
coherent and efficient framework for inter-
sector collaboration emerges. We have also
established that these kinds of schemes require
the community to effect a culture change,manifest by the fact that only significant one-to-
one networking prompted scientists to put their
projects forward. We feel that this could be
down to the unusual nature of the opportunity –
no funds are directly gained by the academic –
confounded with the necessity to make a small
leap into the pharma mindset. However, the
leap required is a small consideration compared
with academics trying to achieve similar out-
comes in-house, because we provide an existing
facility to widen access and accelerate transla-
tional biology.
We strongly believe that there is a wealth of
basic biology in academic life science depart-
ments that can contribute positively towards
pharma’s goals of finding new therapies but that
unlocking this potential requires insight into
academic work-ethic, dedicated industry-grade
facilities and expertise, and specific pump-
priming funding streams. With these elements in
place it is possible to actively unlock the po-
tential and remove the barriers that scientists are
currently experiencing.
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